SetPoint Medical Presents Early Data Showing Bioelectronic Medicine Accelerates Remyelination in Animal Model of Multiple Sclerosis

SetPoint Medical, a clinical-stage biomedical technology company developing a bioelectronic therapy for chronic inflammatory diseases, presented positive data from a study exploring the therapeutic effects of a bioelectronic medicine approach for multiple sclerosis (MS) showing that vagus nerve stimulation (VNS) reduced demyelination and accelerated remyelination. The data were presented at the joint meeting of the European Committee and Americas Committee for Research and Treatment in Multiple Sclerosis (ECTRIMS-ACTRIMS).

Go to the profile of SetPoint Medical
May 09, 2018
1
0

SetPoint Medical Presents Early Data Showing Bioelectronic Medicine Accelerates Remyelination in Animal Model of Multiple Sclerosis

Go to the profile of SetPoint Medical

SetPoint Medical

SetPoint Medical is a privately held biomedical technology company dedicated to treating patients with debilitating inflammatory diseases using bioelectronic therapy. SetPoint’s approach is intended to offer patients and providers an alternative for the treatment of rheumatoid arthritis (RA) and other chronic inflammatory diseases with less risk and cost than drug therapy. SetPoint is developing a novel bioelectronic medicine platform that stimulates the vagus nerve to activate the body’s natural Inflammatory Reflex, which is intended to produce a potent systemic anti-inflammatory effect. The company has published positive results from a first-in-human open-label proof-of-concept trial in rheumatoid arthritis in Proceedings of the National Academy of Sciences (PNAS) and presented positive results at the American College of Rheumatology meeting. Current investors in the company include Morgenthaler Ventures, NEA, Topspin Partners, Medtronic, GlaxoSmithKline’s Action Potential Venture Capital Limited and Boston Scientific.

No comments yet.